HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pop Mart (9992 HK) 2025 Results - More Downside Ahead?

Pre-IPO Shenzhen Mindray Bio-Medical Electronics (A/H Listing) - The Headwinds Still Exist

Pre-IPO Jintan - About the Business Model, the Risks and the Peer Comparison

Pre-IPO Guangdong Huayan Robotics (PHIP Updates) - Some Points Worth the Attention

Pre-IPO Acrobiosystems (A/H Listing) - The Business and the Outlook

Equity Capital Markets

<ul>
<li>The business model of Metis can be summarized as a dual wheel drive model of "platform cooperation + product licensing", with the core competitiveness being AI driven nanomaterial platform NanoForge.</li>
<li>The significant increase in revenue validates the feasibility of its business model. However, the customer concentration, a cumulative loss of RMB1.84 billion, and the uncertainty of R&amp;D pose major risks.</li>
<li>Metis has a prominent scarcity of technology but the commercialization verification is still at an early stage. We think the valuation of Metis would be between <a href="https://www.smartkarma.com/entities/xtalpi-holdings-ltd" target="_blank" data-smartkarma-citation="entities:40369:1" rel="noopener">XtalPi </a>and <a href="https://www.smartkarma.com/entities/insilico-medicine-cayman-topco" target="_blank" data-smartkarma-citation="entities:39890:1" rel="noopener">InSilico Medicine</a>.</li>
</ul>


The business model of Metis can be summarized as a dual wheel drive model of "platform cooperation + product licensing", with the core competitiveness being AI driven nanomaterial platform NanoForge.
The significant increase in revenue validates the feasibility of its business model. However, the customer concentration, a cumulative loss of RMB1.84 billion, and the uncertainty of R&amp;D pose major risks.
Metis has a prominent scarcity of technology but the commercialization verification is still at an early stage. We think the valuation of Metis would be between XtalPi and InSilico Medicine.


Pre-IPO Metis TechBio (PHIP Updates) - The Business Model, the Concerns, and Thoughts on Valuation